Protalix BioTherapeutics
PLX
43 hedge funds and large institutions have $76.5M invested in Protalix BioTherapeutics in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 9 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0.15% less ownership
Funds ownership: 3.52% → 3.38% (-0.15%)
4% less funds holding
Funds holding: 45 → 43 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
36% less capital invested
Capital invested by funds: $120M → $76.5M (-$43.8M)
84% less call options, than puts
Call options by funds: $101K | Put options by funds: $627K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$14.5M |
| 2 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$1.05M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$759K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$738K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$576K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$21.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.89M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.21M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$876K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$612K |
PLX Hedge Fund Activity: Q3 2014 in Review
43 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2014, worth a combined $76.5M — down 36% from $120M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PLX and 7 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $14.5M. The largest seller was Allianz Asset Management, exiting entirely with an estimated $21.2M sold.
- 43 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2014, down from 45 in Q2 2014.
- Funds reported $76.5M of Protalix BioTherapeutics stock for Q3 2014, down 36% quarter-over-quarter.
- 7 funds opened new Protalix BioTherapeutics positions in Q3 2014 and 9 closed out, a net change of -2 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2014 was Consonance Capital Management, an estimated $14.5M added.
- The largest Protalix BioTherapeutics seller in Q3 2014 was Allianz Asset Management, an estimated $21.2M sold.
Based on aggregated 13F filings for Q3 2014.